论文信息 - A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. - 字舞流文

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok | B. Fox | F. Hodi | N. Segal | D. Pardoll | W. Urba | S. Topalian | W. Sharfman | S. Y. Kim | G. Kollia | T. Gajewski | D. McDonald | R. Sanborn